Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewUBP 301
Description: Kainate antagonist
Chemical Name: (αS)-α-Amino-3-[(4-carboxyphenyl)methyl]-3,4-dihydro-5-iodo-2,4-dioxo-1(2H)-pyrimidinepropanoic acid
Purity: ≥98% (HPLC)
Biological Activity for UBP 301
UBP 301 is a potent kainate receptor antagonist (apparent Kd = 5.94 μM). Displays ~ 30-fold selectivity over AMPA receptors.
Technical Data for UBP 301
| M. Wt | 459.2 |
| Formula | C15H14IN3O6 |
| Storage | Store at +4°C |
| Purity | ≥98% (HPLC) |
| CAS Number | 569371-10-4 |
| PubChem ID | 6604913 |
| InChI Key | JHSYCOCOIYSZGI-NSHDSACASA-N |
| Smiles | O=C(C(I)=CN1C[C@H](N)C(O)=O)N(CC2=CC=C(C(O)=O)C=C2)C1=O |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for UBP 301
| Solvent | Max Conc. mg/mL | Max Conc. mM | |
|---|---|---|---|
| Solubility | |||
| DMSO | 2.3 | 5 with gentle warming |
Preparing Stock Solutions for UBP 301
The following data is based on the product molecular weight 459.2. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 0.05 mM | 43.55 mL | 217.77 mL | 435.54 mL |
| 0.25 mM | 8.71 mL | 43.55 mL | 87.11 mL |
| 0.5 mM | 4.36 mL | 21.78 mL | 43.55 mL |
| 2.5 mM | 0.87 mL | 4.36 mL | 8.71 mL |
Molarity Calculator
Molarity Calculator
Calculate the mass, volume, or concentration required for a solution.
Reconstitution Calculator
Reconstitution Calculator
Dilution Calculator
Dilution Calculator
Calculate the dilution required to prepare a stock solution.
Product Datasheets for UBP 301
References for UBP 301
References are publications that support the biological activity of the product.
More et al (2003) Structural requirements for novel willardiine derivatives acting as AMPA and kainate receptor antagonists. Br.J.Pharmacol. 138 1093 PMID: 12684265
If you know of a relevant reference for UBP 301, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: UBP 301, UBP 301 supplier, Kainate, receptor, antagonists, Glutamate, Receptors, iGluR, Ionotropic, UBP301, 1766, Tocris Bioscience
1 Citation for UBP 301
Citations are publications that use Tocris products. Selected citations for UBP 301 include:
Cassé et al (2012) Glutamate controls tPA recycling by astrocytes, which in turn influences glutamatergic signals. J Neurosci 32 5186 PMID: 22496564
Do you know of a great paper that uses UBP 301 from Tocris? Please let us know.
Reviews for UBP 301
There are currently no reviews for this product. Be the first to review UBP 301 and earn rewards!
Have you used UBP 301?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Addiction Poster
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Parkinson's Disease Poster
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.